Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inspire's Denufosol Moves To Phase III For Cystic Fibrosis

This article was originally published in The Pink Sheet Daily

Executive Summary

The clinical program will include two pivotal efficacy studies and long-term carcinogenicity study.

You may also be interested in...



Inspire Begins Phase III Trial Of Denufosol Tetrasodium For Cystic Fibrosis

The firm must complete the 48-week study before submitting an NDA for inhaled denufosol.

Inspire Begins Phase III Trial Of Denufosol Tetrasodium For Cystic Fibrosis

The firm must complete the 48-week study before submitting an NDA for inhaled denufosol.

Pharmaxis To Expedite Bronchitol Phase III Program In Cystic Fibrosis

Pharmaxis preps for pivotal studies of mannitol after Phase II trials showed lung function improvement.

Topics

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel